Gedeon Richter and Pantarhei signed a license and supply agreement for commercialisation of a novel combined oral contraceptive
Gedeon Richter Plc. and Pantarhei Bioscience BV today announced that they have entered into a license and supply agreement to commercialise Pantarhei’s combined oral contraceptive (COC), containing 30 µg ethinyl estradiol, 150 µg levonorgestrel and 50 mg dehydroepiandrosterone (DHEA). The product is under development with successfully completed Phase II trials and is ready for further clinical studies to obtain marketing approval. The geographic scope of the agreement covers Europe, Russia, Latin America and Australia.
Read more: Press Release GedeonRichter – Pantarhei February 4, 2019